Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRÃ), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRÃ for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
IPO Year: 2015
Exchange: NASDAQ
Website: vikingtherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/28/2026 | $89.00 | Buy | Lake Street |
| 5/27/2026 | $83.00 | Buy | Truist |
| 3/26/2026 | Peer Perform | Wolfe Research | |
| 10/29/2025 | $106.00 | Buy | Canaccord Genuity |
| 4/29/2025 | $104.00 | Overweight | Cantor Fitzgerald |
| 4/8/2025 | $30.00 | Neutral | Goldman |
| 2/13/2025 | $102.00 | Sector Outperform | Scotiabank |
| 2/7/2025 | $38.00 | Neutral | Citigroup |
| 12/2/2024 | Overweight | Piper Sandler | |
| 11/22/2024 | $109.00 | Buy | B. Riley Securities |
Fastest customizable press release news feed in the world
SAN DIEGO, May 21, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the William Blair 46th Annual Growth Stock Conference and the Jefferies Global Healthcare Conference in June. Details of the company's participation are as follows:William Blair 46th Annual Growth Stock ConferenceDetails: Viking management will deliver a corporate presentation, followed by a breakout session, and partic
AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (T2DM) rank among the most urgent and costly healthcare problems facing the world today, contributing to surging rates of cardiovascular disease, fatty liver disease, kidney complications and ballooning healthcare expenses. What once represented a specialized class of diabetes treatments has grown into one of the most consequential therapeutic categories in modern medicine, with GLP-1 receptor agonists now fundamentally restructuring how obesity, metabolic disease and potentially even neurodegeneration are treated. Operating in this environment is SureNano Science Ltd. (CSE:S
Oral VK2735 demonstrated early, progressive weight loss from Week 1 through Week 13 without a plateau Dose-dependent weight loss observed across all VK2735 cohorts, with the highest dose achieving a mean reduction of up to 12.2% (26.6 lbs) from baseline at Week 13Baseline characteristics in the ongoing Phase 3 VANQUISH-1 study of VK2735 in adults with obesity were also presented in a second poster at the conferenceSAN DIEGO, May 12, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today presented additional data from its Phase 2 VENTURE-Oral
Poster Presentations Highlight Data from 13-Week Phase 2 VENTURE-Oral Trial of VK2735 and Participant Characteristics from Phase 3 VANQUISH-1 Trial of Subcutaneous VK2735 SAN DIEGO, May 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that it will present two posters on its VK2735 program at the 33rd European Congress on Obesity (ECO) taking place in Istanbul, Türkiye on May 12-15, 2026. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors that Viki
Conference call scheduled for 4:30 p.m. ET today-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled ---- Initiation of Phase 3 Oral VK2735 Trial for Obesity Expected 4Q26 ---- VK2735 Maintenance Dosing Study Ongoing; Data Expected 3Q26 ---- IND Filed for Novel Amylin Agonist VK3019; Phase 1 Trial Initiation Expected 2Q26 ---- Strong Quarter-End Cash Position of $603 Million --SAN DIEGO, April 29, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial resu
Issued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Longeveron Inc. (NASDAQ:LGVN). Key Takeaways: The global anti-aging market generated more than $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science more than doubling to $8.49 billion across 325 deals last year.The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025 — including what researchers are calling the first drug class of "longevity therapeutics" — while big pharma spent more than $65 billion acquiring bi
Conference Call Scheduled for Wednesday, April 29 at 4:30 p.m. Eastern Time SAN DIEGO, April 22, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter of 2026 after the market close on Wednesday, April 29, 2026. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on We
SAN DIEGO, April 10, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will attend multiple upcoming investor conferences. Details of the company's participation are as follows:Raymond James Biotech/BioPharma Conference 2026Details: Viking management will participate in 1-on-1 meetingsConference Date: April 14, 2026Location: New York, NYPiper Sandler Spring Biopharma Symposium 2026Details: Viking
78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 DiabetesSAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its Phase 3 VANQUISH-2 clinical trial of subcutaneous VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2735 is being developed in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity.
SAN DIEGO, March 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at multiple upcoming investor conferences. Details of the company's participation are as follows:Leerink Partners Global Healthcare Conference 2026Details: Viking management will participate in a fireside chat and in 1-on-1 meetingsConference Date: March 8-11, 2026Fireside Chat Timing: 10:40 – 11:10 a.m. Eastern
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4/A - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
Live finance-specific insights
Conference call scheduled for 4:30 p.m. ET today-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled ---- Initiation of Phase 3 Oral VK2735 Trial for Obesity Expected 4Q26 ---- VK2735 Maintenance Dosing Study Ongoing; Data Expected 3Q26 ---- IND Filed for Novel Amylin Agonist VK3019; Phase 1 Trial Initiation Expected 2Q26 ---- Strong Quarter-End Cash Position of $603 Million --SAN DIEGO, April 29, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial resu
Issued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Longeveron Inc. (NASDAQ:LGVN). Key Takeaways: The global anti-aging market generated more than $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science more than doubling to $8.49 billion across 325 deals last year.The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025 — including what researchers are calling the first drug class of "longevity therapeutics" — while big pharma spent more than $65 billion acquiring bi
Conference Call Scheduled for Wednesday, April 29 at 4:30 p.m. Eastern Time SAN DIEGO, April 22, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter of 2026 after the market close on Wednesday, April 29, 2026. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on We
Conference call scheduled for 4:30 p.m. ET today Oral VK2735 to Advance into Phase 3 for Obesity in 3Q26Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Ongoing; VANQUISH-1 Enrollment Complete, VANQUISH-2 Nearing Full EnrollmentVK2735 Maintenance Dosing Study Fully Enrolled; Data Expected 3Q26Novel Amylin Agonist IND Filing Planned This Quarter Strong Quarter-End Cash Position of $706 MillionSAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended
Conference Call Scheduled for Wednesday, February 11 at 4:30 p.m. Eastern Time SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2025 after the market close on Wednesday, February 11, 2026. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m.
Conference call scheduled for 4:30 p.m. ET today Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Proceeding on ScheduleVK2735 Phase 1 Maintenance Dosing Study UnderwayAdditional Phase 2a VENTURE Study Data to be Presented at ObesityWeek in NovemberStrong Quarter-End Cash Position of $715 MillionSAN DIEGO, Oct. 22, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2025, and provided an update on its clinical pipeline and other corporate deve
Conference Call Scheduled for Wednesday, October 22 at 4:30 p.m. Eastern Time SAN DIEGO, Oct. 15, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the third quarter 2025 after the market close on Wednesday, October 22, 2025. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on
Study Achieves Primary and Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight with Once-Daily VK2735 Dosing as Compared to Placebo Up to 12.2% (26.6 lbs) Mean Weight Loss Observed After 13 Weeks of VK2735 Treatment Compared with 1.3% (2.9 lbs) for Placebo Exploratory Assessment of Low Dose Maintenance Treatment Demonstrates Positive Proof of Concept VK2735 Shown to be Safe and Well-Tolerated in 13-Week Study; 99% of GI-specific Treatment Emergent Adverse Events Considered Mild or Moderate Conference Call Scheduled for 8:00 a.m. ET Today SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmac
Conference call scheduled for 4:30 p.m. ET today Phase 3 VANQUISH Registration Trials Underway for VK2735 in ObesityPhase 2 VENTURE-Oral Dosing Trial Enrollment Completed; Top-Line Results Expected 2H25Continued Progress with Amylin Program; IND Planned 4Q25Strong Quarter-End Cash Position of $808 MillionSAN DIEGO, July 23, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2025, and provided an update on its clinical pipeline and other corporate developm
Conference Call Scheduled for Wednesday, July 23 at 4:30 p.m. Eastern Time SAN DIEGO, July 16, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the second quarter 2025 after the market close on Wednesday, July 23, 2025. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, July 23, 2025. To participate on the conference call, please dial (844) 850-0543 from the U.S. or
8-K - Viking Therapeutics, Inc. (0001607678) (Filer)
10-Q - Viking Therapeutics, Inc. (0001607678) (Filer)
8-K - Viking Therapeutics, Inc. (0001607678) (Filer)
DEFA14A - Viking Therapeutics, Inc. (0001607678) (Filer)
DEF 14A - Viking Therapeutics, Inc. (0001607678) (Filer)
SCHEDULE 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
10-K - Viking Therapeutics, Inc. (0001607678) (Filer)
8-K - Viking Therapeutics, Inc. (0001607678) (Filer)
144 - Viking Therapeutics, Inc. (0001607678) (Subject)
144 - Viking Therapeutics, Inc. (0001607678) (Subject)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Lake Street initiated coverage of Viking Therapeutics with a rating of Buy and set a new price target of $89.00
Truist resumed coverage of Viking Therapeutics with a rating of Buy and set a new price target of $83.00
Wolfe Research initiated coverage of Viking Therapeutics with a rating of Peer Perform
Canaccord Genuity initiated coverage of Viking Therapeutics with a rating of Buy and set a new price target of $106.00
Cantor Fitzgerald initiated coverage of Viking Therapeutics with a rating of Overweight and set a new price target of $104.00
Goldman initiated coverage of Viking Therapeutics with a rating of Neutral and set a new price target of $30.00
Scotiabank initiated coverage of Viking Therapeutics with a rating of Sector Outperform and set a new price target of $102.00
Citigroup initiated coverage of Viking Therapeutics with a rating of Neutral and set a new price target of $38.00
Piper Sandler initiated coverage of Viking Therapeutics with a rating of Overweight
B. Riley Securities initiated coverage of Viking Therapeutics with a rating of Buy and set a new price target of $109.00
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
3 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
3 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
Live Leadership Updates
Experienced Industry Leader with More than Two Decades of Global Commercialization and Marketing Expertise SAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Neil Aubuchon as chief commercial officer. Mr. Aubuchon brings more than two decades of biopharmaceutical industry experience spanning leadership roles across global commercial and marketing functions including focus within the cardiometabolic space.
This live feed shows all institutional transactions in real time.
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)